연구
-
-
연구
-
연구업적
연구업적
최근 5년 연구업적 현황
| 연도 | 2023년 | 2022년 | 2021년 | 2020년 | 2019년 | |
|---|---|---|---|---|---|---|
| SCI 논문 발표편수 |
책임 | 173편 | 163편 | 184편 | 135편 | 144편 |
| 공동 | 120편 | 115편 | 136편 | 168편 | 167편 | |
| 합계 | 293편 | 278편 | 320편 | 303편 | 311편 | |
2161. Measurement of multiple solid portions in part-solid nodules for T categorization: Evaluation of prognostic implication
Kim H, Goo JM, Suh YJ, Hwang EJ, Park CM, Kim YT
J Thorac Oncol. 2018 Dec;13(12):1864-1872
Link
2160. Generalization and representativeness of phase III immune checkpoint blockade trials in non-small cell lung cancer.
Yoo SH1, Keam B1,2, Kim M1, Kim TM1,2, Kim DW1,2, Heo DS1,2.
Thorac Cancer. 2018 Jun;9(6):736-744. doi: 10.1111/1759-7714.12641. Epub 2018 Apr 22.
Link
2159. Clinical factors affecting progression-free survival with crizotinib in ALK-positive non-small cell lung cancer.
Ock CY1, Yoo SH1, Keam B1,2, Kim M1, Kim TM1,2, Jeon YK3, Kim DW1,2, Chung DH3, Heo DS1,2.
Korean J Intern Med. 2018 Jun 29. doi: 10.3904/kjim.2018.011. [Epub ahead of print]
Link
2158. Safety and efficacy of immune checkpoint inhibitors for end-stage renal disease patients undergoing dialysis: a retrospective case series and literature review.
Cheun H1, Kim M2, Lee H2, Oh KH2, Keam B3,4.
Invest New Drugs. 2018 Oct 8. doi: 10.1007/s10637-018-0673-y. [Epub ahead of print]
Link
2157. Inhibition of MEK with trametinib enhances the efficacy of anti-PD-L1 inhibitor by regulating anti-tumor immunity in head and neck squamous cell carcinoma.
Kang SH1, Keam B1,2, Ahn YO1,3, Park HR1, Kim M2, Kim TM1,2, Kim DW1,2, Heo DS1,2.
Oncoimmunology. 2018 Sep 21;8(1):e1515057. doi: 10.1080/2162402X.2018.1515057. eCollection 2019.
Link
2156. Comprehensive analysis of the tumor immune micro-environment in non-small cell lung cancer for efficacy of checkpoint inhibitor.
Seo JS1,2,3,4, Kim A5,6,7, Shin JY6,8, Kim YT9,10,11.
Sci Rep. 2018 Oct 1;8(1):14576. doi: 10.1038/s41598-018-32855-8.
Link
2155. Whole Exome and Transcriptome Analyses Integrated with Microenvironmental Immune Signatures of Lung Squamous Cell Carcinoma.
Seo JS#1,2,3,4, Lee JW#2,3, Kim A#2,3, Shin JY#2,4, Jung YJ5, Lee SB5, Kim YH5, Park S6, Lee HJ6, Park IK6, Kang CH6, Yun JY2,4, Kim J2,4, Kim YT7,5,6.
Cancer Immunol Res. 2018 Jul;6(7):848-859. doi: 10.1158/2326-6066.CIR-17-0453. Epub 2018 May 2.
Link
2154. A radiosensitivity gene signature and PD-L1 predict the clinical outcomes of patients with lower grade glioma in TCGA.
Jang BS1, Kim IA2.
Radiother Oncol. 2018 Aug;128(2):245-253. doi: 10.1016/j.radonc.2018.05.003. Epub 2018 May 18.
Link
2153. Prediction of Pseudoprogression versus Progression using Machine Learning Algorithm in Glioblastoma.
Jang BS1, Jeon SH1, Kim IH1,2, Kim IA3,4.
Sci Rep. 2018 Aug 21;8(1):12516. doi: 10.1038/s41598-018-31007-2.
Link
2152. Plasma-based protein biomarkers can predict the risk of acute graft-versus-host disease and non-relapse mortality in patients undergoing allogeneic hematopoietic stem cell transplantation.
Shin J1, Dan K2, Han D2, Kim JW3, Kim KK4, Koh Y1, Shin DY1, Hong J1, Yoon SS1, Park S5, Song SH6, Kim I7.
Blood Cells Mol Dis. 2019 Feb;74:5-12. doi: 10.1016/j.bcmd.2018.10.001. Epub 2018 Oct 4.
Link